Investigator Initiated Studies – ER+ Breast Cancer with Imlunestrant

Lilly Oncology is dedicated to delivering innovative treatment approaches with the goal of improving the outcomes of people living with cancer. We are driven to accelerate the pace and progress of cancer care by developing a broad portfolio of therapies, including those tailored to unique patients and those that modulate the immune system. Lilly’s commitment to improving the length and quality of people’s lives is achieved through its internal drug development programs and its support of Investigator Initiated Research.

Therapeutic Area

Oncology

Region

USA

Submission Countdown

Days

Hours

Support to answer important medical questions in the following indications:

ER+ Breast Cancer:
- Novel combinations with targeted treatments in Phase 2 development or later.
- Patient preference studies.
- Translational and/or diagnostic studies for patient identification.

Material only support will be considered for HR+ gynecologic indication.

Out of scope:

Studies that overlap with ongoing or planned clinical development.
Head to head comparisons with other oral SERDs.

PIRA™ suggested Proposal

PIRA™ proposals are AI generated and are not reviewed or endorsed by the sponsoring company.